BRPI0821116A2 - Composto, composição farmacêutica que o contem, uso deste e método para tratar qualquer mamífero afetado por câncer - Google Patents

Composto, composição farmacêutica que o contem, uso deste e método para tratar qualquer mamífero afetado por câncer

Info

Publication number
BRPI0821116A2
BRPI0821116A2 BRPI0821116-7A BRPI0821116A BRPI0821116A2 BR PI0821116 A2 BRPI0821116 A2 BR PI0821116A2 BR PI0821116 A BRPI0821116 A BR PI0821116A BR PI0821116 A2 BRPI0821116 A2 BR PI0821116A2
Authority
BR
Brazil
Prior art keywords
cancer
compound
treating
pharmaceutical composition
composition containing
Prior art date
Application number
BRPI0821116-7A
Other languages
English (en)
Inventor
Alberto Rodríguez Vicente
Carmen Murcia Pérez
Francisco Sánchez Sancho
María Del Carmen Cuevas Marchante
María Garranzo García-Ibarrola
Cristina Mateo Urbano
Isabel Digón Juárez
Original Assignee
Pharma Mar Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma Mar Sa filed Critical Pharma Mar Sa
Publication of BRPI0821116A2 publication Critical patent/BRPI0821116A2/pt
Publication of BRPI0821116B1 publication Critical patent/BRPI0821116B1/pt
Publication of BRPI0821116B8 publication Critical patent/BRPI0821116B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/51—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/695—Silicon compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/30—Oxygen atoms, e.g. delta-lactones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/32—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Dermatology (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Compounds Of Unknown Constitution (AREA)
BRPI0821116A 2007-12-20 2008-12-19 composto, composição farmacêutica que o contem, uso deste e processo para a preparação do mesmo BRPI0821116B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07123882.8 2007-12-20
EP07123882 2007-12-20
PCT/EP2008/068049 WO2009080761A1 (en) 2007-12-20 2008-12-19 Antitumoral compounds

Publications (3)

Publication Number Publication Date
BRPI0821116A2 true BRPI0821116A2 (pt) 2015-08-11
BRPI0821116B1 BRPI0821116B1 (pt) 2020-02-18
BRPI0821116B8 BRPI0821116B8 (pt) 2021-05-25

Family

ID=40580474

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0821116A BRPI0821116B8 (pt) 2007-12-20 2008-12-19 composto, composição farmacêutica que o contem, uso deste e processo para a preparação do mesmo
BRPI0821114A BRPI0821114B8 (pt) 2007-12-20 2008-12-19 Composto antitumoral, composição farmacêutica, uso de um composto antitumoral, uso de uma composição farmacêutica, e processo para a preparação do referido composto

Family Applications After (1)

Application Number Title Priority Date Filing Date
BRPI0821114A BRPI0821114B8 (pt) 2007-12-20 2008-12-19 Composto antitumoral, composição farmacêutica, uso de um composto antitumoral, uso de uma composição farmacêutica, e processo para a preparação do referido composto

Country Status (27)

Country Link
US (4) US9187445B2 (pt)
EP (3) EP2231590B9 (pt)
JP (3) JP5727228B2 (pt)
KR (3) KR101541436B1 (pt)
CN (4) CN101903367B (pt)
AT (1) ATE549313T1 (pt)
AU (2) AU2008341671B2 (pt)
BR (2) BRPI0821116B8 (pt)
CA (2) CA2715203C (pt)
CY (1) CY1117245T1 (pt)
DK (2) DK2231633T3 (pt)
ES (3) ES2442140T3 (pt)
HK (3) HK1147998A1 (pt)
HR (2) HRP20120464T1 (pt)
IL (3) IL206397A (pt)
MX (2) MX2010006796A (pt)
MY (3) MY164533A (pt)
NZ (3) NZ597526A (pt)
PL (2) PL2231590T3 (pt)
PT (2) PT2231590E (pt)
RS (2) RS52343B (pt)
RU (3) RU2493147C2 (pt)
SG (2) SG170779A1 (pt)
SI (2) SI2231633T1 (pt)
UA (3) UA106967C2 (pt)
WO (2) WO2009080769A1 (pt)
ZA (3) ZA201004018B (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS52343B (en) 2007-12-20 2012-12-31 Pharma Mar S.A. ANTITUMOR UNITS
CN104039315B (zh) * 2012-01-05 2016-08-24 花王株式会社 用于降低感觉刺激的制剂
TWI631119B (zh) 2013-04-16 2018-08-01 愛杜西亞製藥有限公司 抗菌雙芳香族衍生物
GB201309807D0 (en) * 2013-05-31 2013-07-17 Pharma Mar Sau Antibody drug conjugates
CN108467378A (zh) * 2017-02-23 2018-08-31 复旦大学 一种二氢吡喃酮类化合物及其制备方法和用途
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5142056A (en) * 1989-05-23 1992-08-25 Abbott Laboratories Retroviral protease inhibiting compounds
US4855086A (en) * 1982-10-15 1989-08-08 Burroughs Wellcome Co. Novel pesticides, preparation and use
JPS61109717A (ja) * 1984-11-02 1986-05-28 Teruhiko Beppu 抗腫瘍剤
JPH06504547A (ja) * 1990-12-28 1994-05-26 ジョージア・テック・リサーチ・コーポレーション ペプチドケトアミド、ケト酸およびケトエステル
JPH0539283A (ja) * 1991-01-31 1993-02-19 Suntory Ltd 新規物質Ｓ−５９９１７ａ及びその製造方法
ZA938019B (en) 1992-11-13 1995-04-28 Upjohn Co Pyran-2-ones and 5,6-dihydropyran-2-ones useful for treating HIV and other retroviruses
US5523456A (en) * 1994-09-29 1996-06-04 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5681847A (en) * 1995-12-05 1997-10-28 Harbor Branch Oceanographic Institution, Inc. Methods of using discodermolide compounds
US5834506A (en) 1996-11-01 1998-11-10 Warner-Lambert Company Dihydropyrones with improved antiviral activity
US5840974A (en) * 1996-12-04 1998-11-24 Britisch Biotech Pharmaceuticals, Ltd. Metalloproteinase inhibitors
US6380400B1 (en) 1998-09-11 2002-04-30 Victor Fedij Methods of making dihydropyrone HIV protease inhibitors
NZ510013A (en) 1998-09-11 2003-11-28 Warner Lambert Co Dihydropyrones with selected heterocycles replacing the phenyls bearing polar substituents used as HIV protease inhibitors
AU2000241948A1 (en) * 2000-04-04 2001-10-15 Novartis Ag Method for treating cells resistant to antineoplastic agents
ES2532607T3 (es) * 2002-03-04 2015-03-30 Merck Hdac Research, Llc Métodos de inducción de la diferenciación terminal
JP2006528611A (ja) * 2003-07-25 2006-12-21 ノバルティス アクチエンゲゼルシャフト 置換ラクタムおよびそれらの抗がん剤としての使用
RU2006142690A (ru) * 2004-06-03 2008-06-10 Козан Байосайенсиз Инкорпорейтед (Us) Соединения лептомицина
US7446196B2 (en) 2004-06-03 2008-11-04 Kosan Biosciences, Incorporated Leptomycin compounds
WO2007014423A1 (en) * 2005-08-02 2007-02-08 Medvet Science Pty, Ltd. Exercise apparatus
CN102336730A (zh) 2006-06-16 2012-02-01 马尔药品公司 抗肿瘤二羟基吡喃-2-酮化合物
RS52343B (en) 2007-12-20 2012-12-31 Pharma Mar S.A. ANTITUMOR UNITS

Also Published As

Publication number Publication date
IL206396A (en) 2014-05-28
CN101903367A (zh) 2010-12-01
MX2010006795A (es) 2010-10-26
US9827257B2 (en) 2017-11-28
PT2231590E (pt) 2012-06-25
KR20100100979A (ko) 2010-09-15
NZ597526A (en) 2012-06-29
HK1147990A1 (en) 2011-08-26
CN101903367B (zh) 2015-08-05
EP2231590B1 (en) 2012-03-14
ZA201106371B (en) 2013-05-29
IL206396A0 (en) 2010-12-30
EP2231590B9 (en) 2012-08-15
RU2528393C9 (ru) 2015-01-10
JP5860088B2 (ja) 2016-02-16
RS53140B (en) 2014-06-30
RU2528393C1 (ru) 2014-09-20
EP2597091A1 (en) 2013-05-29
IL229594A0 (en) 2014-01-30
MX2010006796A (es) 2010-10-26
CN101903337A (zh) 2010-12-01
ES2384420T3 (es) 2012-07-04
RU2010130253A (ru) 2012-01-27
ES2578606T3 (es) 2016-07-28
SG170778A1 (en) 2011-05-30
CY1117245T1 (el) 2017-04-05
SI2231590T1 (sl) 2012-10-30
EP2231633A1 (en) 2010-09-29
KR101579553B1 (ko) 2015-12-22
RU2489429C2 (ru) 2013-08-10
KR20150076265A (ko) 2015-07-06
US20110034549A1 (en) 2011-02-10
BRPI0821114B8 (pt) 2021-11-09
EP2231590A1 (en) 2010-09-29
EP2231633B1 (en) 2013-10-30
CN101903337B (zh) 2013-12-18
CA2710087A1 (en) 2009-07-02
JP5529038B2 (ja) 2014-06-25
SI2231633T1 (sl) 2014-02-28
IL229594A (en) 2016-02-29
HK1147998A1 (en) 2011-08-26
RU2013112003A (ru) 2014-08-20
AU2008341670B2 (en) 2012-04-19
AU2008341671A1 (en) 2009-07-02
HRP20120464T1 (hr) 2012-07-31
US9750759B2 (en) 2017-09-05
HRP20140015T1 (hr) 2014-02-14
ZA201004017B (en) 2011-12-28
PL2231633T3 (pl) 2014-03-31
NZ586012A (en) 2011-11-25
US20100280108A1 (en) 2010-11-04
AU2008341670A1 (en) 2009-07-02
CA2710087C (en) 2015-06-02
US20120041063A2 (en) 2012-02-16
RU2493147C2 (ru) 2013-09-20
CN102174058A (zh) 2011-09-07
JP2011506578A (ja) 2011-03-03
BRPI0821114A2 (pt) 2015-06-16
ZA201004018B (en) 2011-12-28
MY148651A (en) 2013-05-15
DK2231633T3 (da) 2014-01-20
UA119963C2 (uk) 2019-09-10
PL2231590T3 (pl) 2012-09-28
ATE549313T1 (de) 2012-03-15
BRPI0821116B1 (pt) 2020-02-18
PT2231633E (pt) 2014-01-20
WO2009080769A1 (en) 2009-07-02
BRPI0821116B8 (pt) 2021-05-25
US9187445B2 (en) 2015-11-17
US20150342972A1 (en) 2015-12-03
UA106967C2 (uk) 2014-11-10
WO2009080761A1 (en) 2009-07-02
IL206397A (en) 2014-01-30
CA2715203A1 (en) 2009-07-02
IL206397A0 (en) 2010-12-30
CN102190643B (zh) 2015-02-25
HK1180678A1 (zh) 2013-10-25
BRPI0821114B1 (pt) 2021-09-08
UA104281C2 (ru) 2014-01-27
KR101541436B1 (ko) 2015-08-03
KR101639772B1 (ko) 2016-07-15
DK2231590T3 (da) 2012-07-09
JP5727228B2 (ja) 2015-06-03
US8710264B2 (en) 2014-04-29
SG170779A1 (en) 2011-05-30
MY155342A (en) 2015-10-15
EP2597091B1 (en) 2016-04-20
NZ586013A (en) 2012-02-24
KR20100125226A (ko) 2010-11-30
JP2011506575A (ja) 2011-03-03
CN102190643A (zh) 2011-09-21
RS52343B (en) 2012-12-31
MY164533A (en) 2017-12-29
US20150344454A1 (en) 2015-12-03
RU2010130180A (ru) 2012-01-27
CA2715203C (en) 2015-09-08
AU2008341671B2 (en) 2012-07-26
JP2014133752A (ja) 2014-07-24
ES2442140T3 (es) 2014-02-25

Similar Documents

Publication Publication Date Title
CY1121135T1 (el) Ενωσεις υποκατεστημενης τετρακυκλιnhς για την θεραπευτικη αγωγη φλεγμονωδων διαταραχων του δερματος
EP1961418A4 (en) USE OF ISOTHIOCYANATE-BASED COMPOUNDS IN THE TREATMENT OF PROSTATIC DISEASES AND SKIN CANCER
ECSP067062A (es) Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso
CO6270257A2 (es) Derivados de piridazinona
ECSP077401A (es) Medicamentos que contienen compuestos de carbonilo y su uso
BRPI0606112A2 (pt) 3 - heteroaril - 3 - hidróxi - 2 - amino - propil aminas e compostos relacionados, bem como uso dos mesmos e composição farmacêutica
CL2007003520A1 (es) Compuestos derivados de heterociclos sustituidos con morfolina, inhibidores de la actividad pi3 quinasa; composicion farmaceutica que comprende a dichos compuestos; kit farmaceutico; y su uso para el tratamiento profilactico o terapeutico del cancer.
CL2010000188A1 (es) Metodo para el tratamiento de una infeccion en un sujeto que comprende la administracion de 9-[(2,2-dimetil-propilamino)-metil]-minociclina o de una sal de la misma; composicion farmaceutica que comprende dicho compuesto; y su uso.
CL2007003138A1 (es) Compuestos derivados de anilinopiperazina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
UY29633A1 (es) Derivados de oxindol
DOP2006000268A (es) Agentes antibacterianos
BRPI0811816A2 (pt) "forma de dosagem de picoplatina estabilizada, método para preparar uma forma de dosagem de picoplatina estabilizada, composições, kit, pluralidade de kits, método para tratamento de câncer e uso de uma quantidade eficaz da forma de dosagem"
CR8696A (es) Beta-carbolinas utiles para tratar enfermedades inflamatorias
CL2008001782A1 (es) Uso de una composicion que comprende un compuesto derivado de heterociclo para tratar o prevenir la perdida de flujo intestinal; composicion que comprende dicho compusto; y kit que comprende la composicion.
BRPI0821116A2 (pt) Composto, composição farmacêutica que o contem, uso deste e método para tratar qualquer mamífero afetado por câncer
MX2008015775A (es) Compuestos y composiciones para tratamiento de cancer.
ECSP099389A (es) Nuevas formas cristalinas
BR112012027393A2 (pt) composto da fórmula geral i, composição farmacêutica, uso de um composto e método de tratamento de qualquer mamífero, notadamente um humano, afetado por câncer
CL2007003847A1 (es) Compuestos derivados de pirimidinas 2,4,5 tri-sustituidas; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento del cancer.
ECSP077390A (es) Uso de epotilonas en el tratamiento de metástasis en hueso y tumores o tipos de cancer en hueso
ATE547414T1 (de) 4-oxadiazolylpiperidinverbindungen und deren verwendung
CR9122A (es) Compuestos de carbamato para utilizar en el tratamiento de padecimientos degenerativos
CL2007003792A1 (es) Compuestos derivados de piperidinas sustituidas que contienen una porcion de heteroarilamida o heteroarilfenil; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
CY1114328T1 (el) Αμινοκινολονες ως gsk-3 αναστολεις

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 18/02/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 19/12/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 16A ANUIDADE.